Clinical Trial

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Moderate to Severe Hidradenitis Suppurativa

Enrolling by Invitation Phase 3
View on ClinicalTrials.gov →
Summary
This is a study to evaluate the long-term safety, tolerability, and efficacy of sonelokimab in participants with moderate to severe hidradenitis suppurativa who were previously enrolled in a parental study.
Protocol Amendment History 2 changes
notable Trial sites expanded: 160 -> 166 locations 2026-06-09
notable Trial sites expanded: 88 -> 160 locations 2026-05-07
Trial Details
NCT Number NCT07007637
Lead Sponsor MoonLake Immunotherapeutics AG
Conditions Hidradenitis Suppurativa
Enrollment 835 participants
Start Date 2025-06-27
Primary Completion 2028-06-13 (estimated)
Study Completion 2028-06-13 (estimated)
Updated on ClinicalTrials.gov 2026-06-08